Syntara Limited

Today is World Parkinson’s Day. It’s a time to raise awareness and understanding of Parkinson’s disease, a progressive neurological condition that affects millions of people worldwide. At Syntara, our work in neuroinflammation includes SNT-4728, currently in a Phase 2 clinical study in patients with isolated REM sleep behaviour disorder (iRBD), a condition recognised as one of the strongest early indicators of future Parkinson’s disease and related neurodegenerative disorders. The study is evaluating whether SNT-4728 can reduce neuroinflammation in key brain regions linked to disease progression, as well as assess its impact on clinical symptoms. By focusing on this early stage, the program aims to better understand whether intervening before the onset of overt neurodegenerative disease can influence disease biology. Top-line results from the study are expected in Q2 CY26. For more information on Parkinson's, visit: parkinson.org/awareness $SNT

“It’s a well covered stock, backed with smart money, with a pipeline which is going to deliver real effective news flow in the next 12 months," CEO Gary Phillips said. In this clip from the NWR Healthcare Conference, Syntara’s CEO highlights the Company’s institutional shareholder base, analyst coverage, and a clinical pipeline positioned to deliver multiple data read-outs in 2026. With a strong cash position and a proven track record in doing deals, the focus remains on progressing studies and defining what comes next. Watch the full $SNT presentation here: youtube.com/watch?v=NMG7hC…

The replay of our CEO, Gary Phillips’presentation from today’s NWR Virtual Healthcare Conference is now available. Watch the full replay here: youtu.be/NMG7hCfj8-I?si… $SNT #HealthcareConference #Biotech #InvestorUpdate #Webinar #Fibrosis #MedicalResearch #ASX @NWRcomms

REMINDER | CEO Gary Phillips will present at the @NWRcomms Virtual Healthcare Conference tomorrow (25 March 2026), at 2:00pm AEDT. Investors, shareholders, and interested parties are invited to register for the session here: ➡️ us02web.zoom.us/webinar/regist… A recording will be available after the live session via the same link, the Company’s website, and social media channels. Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au. For more information, visit: nwrcommunications.com/events/healthc… $SNT #Syntara #HealthcareConference #Biotech #InvestorUpdate #Webinar #Fibrosis #MedicalResearch #ASX

Some 80% of people who develop Parkinson's present with this sleep disorder first. Syntara's treating it | Media coverage The Market Link. hotcopper.com.au/news/asx-news/… $SNT #Parkinsons #biotech

Media coverage | Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that hotcopper.com.au/news/asx-news/… $SNT #Syntara #HotCopper #Media #Biotech

We've received a milestone payment of approximately A$1.7 million from Parkinson’s UK, triggered by dosing of the final patient in our Phase 2 clinical trial of SNT-4728. SNT-4728 is being evaluated as a potential treatment targeting neuroinflammation associated with early-stage Parkinson’s disease in individuals diagnosed with isolated REM sleep behaviour disorder (iRBD), a condition recognised as one of the strongest known early indicators of future Parkinson’s disease and related neurodegenerative disorders. Top-line results from the trial, including both safety and efficacy endpoints, are expected in Q2 CY26. Read the full ASX Announcement here: cdn-api.markitdigital.com/apiman-gateway… $SNT #Syntara #ASX #Biotech #ClinicalTrials #ParkinsonsDisease #Neuroinflammation #iRBD

We're pleased to share that CEO Gary Phillips will present at the @NWRcomms Virtual Healthcare Conference on Wednesday, 25 March 2026, at 2:00pm AEDT. Investors, shareholders, and interested parties are invited to register for the session here: ➡️ us02web.zoom.us/webinar/regist… A recording will be available after the live session via the same link, the Company’s website, and social media channels. Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au. For more information, visit: nwrcommunications.com/events/healthc… $SNT #Syntara #HealthcareConference #Biotech #InvestorUpdate #Webinar #ASX

. @SyntaraTx (#ASX: $SNT) is rated Speculative Buy by Euroz Hartleys with a $0.22 price target, implying ~659% upside to the current share price of $0.029. The note follows a major sector deal after @sanofi agreed to license #rovadicitinib from Sino Biopharmaceutical in a transaction worth up to US$1.53 billion, highlighting the growing commercial interest in new treatments for #myelofibrosis. Euroz says the size of the deal “speaks to the perceived value of the space,” and sees it as a positive read-through for Syntara’s lead asset amsulostat (SNT-550). In its Phase 2 study, the drug delivered encouraging results when combined with the standard-of-care therapy ruxolitinib, with 73% of patients achieving a ≥50% reduction in total symptom score and 44% achieving a ≥25% reduction in spleen volume. Euroz maintains its $0.22 risked valuation, noting its $0.41 unrisked valuation is based solely on the myelofibrosis opportunity and does not include value from Syntara’s broader pipeline.

Three Shots, One Strategy: The Syntara (#ASX: $SNT) Story | Media coverage by The Armchair Analyst, written by Jason Segal thearmchairanalyst.com/p/three-shots-…

We've released our half-year report for the period ending 31 December 2025. View the full report here: cdn-api.markitdigital.com/apiman-gateway…

Syntara has been included in a recent @LivewireMarkets piece highlighting six ASX biotech firms to watch. $SNT The article references our clinical-stage programs, including results expected in myelodysplastic syndrome, as a key area to watch in the year ahead. With five separate data read-outs expected in 2026 across our clinical portfolio, we enter the year with multiple potential value-defining milestones. livewiremarkets.com/wires/is-csl-g…

Euroz Hartleys 2026 Healthcare Forum: February 2026 Investor Presentation: cdn-api.markitdigital.com/apiman-gateway… $SNT #Euroz #biotechinvestors #biotech #SNT

In case you missed it - our latest investor webinar replay is now available. CEO Gary Phillips and Non-Executive Director Hashan De Silva, CFA provided commentary on Syntara’s extensive clinical pipeline for 2026, including ongoing discussions with the FDA regarding the development plan for amsulostat in myelofibrosis, interim safety and efficacy data expected from the MDS studies, trial initiation in pancreatic cancer, progress across the skin scarring program, and Phase 2 top-line data in Q2 from the SNT-4728 iRBD study. With five separate data read-outs expected this year, 2026 represents a significant period for the Company. Shareholders, investors and interested parties can view the replay below. youtu.be/XiWqRdZKWhE?si… $SNT

Today is World Cancer Day. It’s a moment to recognise the millions of people around the world living with cancer and the families, caregivers and clinicians who support them every day. At @SyntaraTx, our clinical programs in #myelofibrosis, myelodysplastic syndrome and pancreatic cancer are driven by the belief that continued research and collaboration matter. Every clinical trial represents patients who step forward in the hope of progress, and researchers working to better understand complex disease biology. On World Cancer Day, we acknowledge their courage and commitment and reaffirm our focus on advancing research in areas of high unmet medical need. #WorldCancerDay #CancerResearch #ClinicalTrials #MedicalResearch #Syntara $SNT #ASXBiotech #PancreaticCancer #MyelodysplasticSyndrome

Syntara CEO Gary Phillips will present at the Euroz Hartleys Healthcare Forum on Thursday, 5 February 2026. The presentation will provide an update on Syntara’s clinical pipeline and outlook for 2026, including multiple data read-outs expected across the Company’s programs. #Euroz #biotechinvestors #biotech $SNT

2026 Outlook Webinar Presentation: February 2026 View the full presentation here: cdn-api.markitdigital.com/apiman-gateway… $SNT #Syntara #Presentaion #ASXNews #Biotech

REMINDER | Join our upcoming investor webinar. Syntara CEO Gary Phillips and Non-Executive Director Hashan De Silva will host an investor webinar to provide company outlook and commentary on Syntara’s extensive clinical pipeline for 2026. With five data read-outs expected during 2026, the session will focus on the opportunities ahead and provide shareholders and interested parties the chance to ask questions. 📅 11:00am AEDT – Tuesday 3 February 2026 Register here: us02web.zoom.us/webinar/regist… Questions can be submitted live during the webinar or sent in advance to matt@nwrcommunications.com.au. A replay will be available shortly following the conclusion of the live session. For more info: imagesignal.commsec.com.au/docserver/0305… #SNT #Syntara #Webinar #Biotech #ASXNews

Join our upcoming investor webinar. Syntara CEO Gary Phillips and Non-Executive Director Hashan De Silva will host an investor webinar to provide company outlook and commentary on Syntara’s extensive clinical pipeline for 2026. With five data read-outs expected during 2026, the session will focus on the opportunities ahead and provide shareholders and interested parties the chance to ask questions. 📅 11:00am AEDT – Tuesday 3 February 2026 Register here: us02web.zoom.us/webinar/regist… Questions can be submitted live during the webinar or sent in advance to matt@nwrcommunications.com.au. A replay will be available shortly following the conclusion of the live session. #SNT #Syntara #Webinar #Biotech #ASXNews

Our CEO Gary Phillips provides a brief overview of today’s December Quarterly and what it means for Syntara in 2026. The quarter saw continued momentum for our lead asset, amsulostat, including presentation of final Phase 2a myelofibrosis data at the American Society of Hematology and initiation of the Phase 2 MESSAGE trial in transfusion-dependent MDS. Interim data from both MDS studies are expected around mid-2026. Across the broader pipeline, SNT-4728 has completed recruitment in the Phase 2 iRBD study with results expected in Q2 2026, and SNT-9465 is progressing into a hypertrophic scar study with data anticipated in the second half of the year. With five separate data read-outs expected in 2026 and a proforma cash balance of $12.3 million at 31 December, the year ahead is shaping up to be a pivotal period for Syntara. Gary and Board member Hashan De Silva will discuss the Quarterly in more detail at next week’s webinar. WEBINAR DETAILS 11:00am AEDT – Tuesday 3 February 2026 Click here to register: us02web.zoom.us/webinar/regist… Watch the short $SNT update below. #SNT #Syntara #Webinar #Biotech #ASXNews